Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.

ABSTRACT:

Background

The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood-based multigene assay for management of neuroendocrine tumors (NETs) in a real-world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch-and-wait) were evaluated.

Materials and methods

Patients with NETs (n = 100) were followed for 6-12 months. Patients' primary tumors were gastroenteropancreatic (68%), lung 20%, and of unknown origin (12%). Characteristics included well-differentiated, low-grade tumors (97%), stage IV disease (96%); treatment with surgery (70%); and drug treatment (56%). NETest was measured at each visit and disease status

SUBMITTER: Liu E 

PROVIDER: S-EPMC6656500 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature